

# GUCY2C/Guanylyl cyclase C

Catalog # PVGS1814

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">XP_005570270.1</a> Cynomolgus
<b>Sequence</b>	Ser24-Gln430
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Biological Activity</b>	Immobilized GUCY2C/Guanylyl cyclase C, His, Cynomolgus (Cat.No.: Z03914) at 5 $\mu$ g/ml (100 $\mu$ l/Well) on the plate can bind Anti-GUCY2C Antibody, hFc Tag
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	47.2 kDa
<b>Formulation</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, pH 7.4 .
<b>Reconstitution</b>	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O more than 100 $\mu$ g/ml.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
--------------------------	--

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.